Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Net Income/ Starting Line | 959.80 | 837.37 | 767.47 | 723.10 |
Depreciation/ Depletion | 69.68 | 65.77 | 68.19 | 79.28 |
Non- Cash Items | -254.26 | -108.46 | -24.27 | -123.25 |
Changesin Working Capital | -193.22 | -310.45 | -0.64 | -101.20 |
Cashfrom Operating Activities | 582.00 | 484.23 | 810.75 | 577.93 |
Capital Expenditures | -31.22 | -44.04 | -34.64 | -44.23 |
Other Investing Cash Flow Items Total | 39.94 | 851.89 | -370.87 | 462.82 |
Cashfrom Investing Activities | 8.72 | 807.85 | -405.51 | 418.59 |
Financing Cash Flow Items | -1.79 | -0.96 | -1.99 | -3.53 |
Total Cash Dividends Paid | -541.57 | -1,525.50 | -506.64 | -677.62 |
Issuance( Retirement)of Debt Net | -18.13 | -16.87 | -15.62 | -14.98 |
Cashfrom Financing Activities | -561.49 | -1,543.32 | -524.24 | -696.14 |
Net Changein Cash | 29.23 | -251.25 | -119.00 | 300.38 |
Cash Interest Paid | 1.79 | 1.40 | 1.99 | 3.53 |
Cash Taxes Paid | 254.23 | 264.71 | 120.51 | 146.96 |
Glaxosmithkline Pharmaceuticals Dividend Glaxosmithkline Pharmaceuticals Bonus Glaxosmithkline Pharmaceuticals News Glaxosmithkline Pharmaceuticals AGM Glaxosmithkline Pharmaceuticals Rights Glaxosmithkline Pharmaceuticals Splits Glaxosmithkline Pharmaceuticals Board Meetings Glaxosmithkline Pharmaceuticals Key Metrics Glaxosmithkline Pharmaceuticals Shareholdings Glaxosmithkline Pharmaceuticals Profit Loss Glaxosmithkline Pharmaceuticals Balance Sheet Glaxosmithkline Pharmaceuticals Q1 Results Glaxosmithkline Pharmaceuticals Q2 Results Glaxosmithkline Pharmaceuticals Q3 Results Glaxosmithkline Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks